Tuesday, 6 February 2018

Press Release: BioLargo Completes Study of Breakthrough Water Treatment Technology for Poultry Process Water and Municipal Wastewater Treatment

Westminster CA – February 6, 2018 – BioLargo Inc. (OTCQB: BLGO) (the “Company”), an innovator of sustainable science and technology and full-service environmental engineering company, announced today the completion of a study that demonstrates the effectiveness of its Advanced Oxidation System (“AOS”) water treatment platform for treatment of poultry wastewater and municipal tertiary wastewater. The study was partially funded by the Metropolitan Water District (“MWD”) of Southern California’s Innovative Conservation Program (“ICP” - http://mwdh2o.com/ICP). A report of the study’s conclusions can be found online at MWD’s ICP website, at http://www.bewaterwise.com/ICP_projects.shtml.
To highlight the report, the AOS was shown to:
  • To be at least 50% more energy-efficient in comparison to incumbent technologies (U.V.  and Ozone);
  • Be forecasted to involve far less maintenance cost than chlorination; and
  • Could present an effective and cost-efficient alternative to market-available tertiary treatment technologies, and stands to afford major water and costs savings to the Californian municipal wastewater market
These results complement the AOS’s prior proof-of-claim results that prove the AOS can:
  • Completely remove polyaromatic hydrocarbons;
  • Inactivate 6 logs of bacterial pathogens (Salmonella enterica and Escherichia coli);
  • Inactivate 4 logs of virus surrogate; and
  • Remove naphthenic acids (up to 80% in single pass)
BioLargo President and Chief Executive Officer Dennis Calvert commented, “This report demonstrates the enormous cost and water recycling benefits the AOS will have for end-users. We recently acquired a world-class team of engineers (www.BioLargoEngineering.com), to provide problem-solving solutions for clients and support the scale-up and commercial preparation for the AOS already underway. We are also evaluating a number of strategic alliance, public funding opportunities, pilots and customer opportunities for our AOS technology.”

About BioLargo, Inc.
BioLargo, Inc. is an innovator of sustainable science and technology, and full-service environmental engineering company that makes life better by delivering world-class products and services across a broad range of industries, with a drive to deliver clean water, clean air and advanced wound care. More information can be found about the company at www.BioLargo.com. Its engineering division (www.BioLargoEngineering.com) features an exceptional team of experienced specialists dedicated to integrity, reliability, safety, and environmental stewardship. It water division (www.BioLargoWater.com) showcases its emerging technology, the Advanced Oxidation System “AOS”, an award-winning product, having been awarded more than 55 research grants and counting, specifically designed to eliminate common, troublesome, and dangerous contaminants in water in a fraction of the time and cost of current technologies. Its odor division features sustainable odor elimination products including its CupriDyne Clean (www.CupriDyne.com) Industrial Odor Eliminator, a product currently serving the leading solid waste handling and wastewater treatment companies as well as any industry that that contends with malodors, VOC’s or similar air quality related problems. Its personal care product division features products in the pet, equine, military supply and consumer markets, and include the Nature’s Best Solution® and Deodorall® brands (www.OdorNoMore.com). Its medical division (www.ClyraMedical.com) focuses on advanced wound care management, featuring effective and gentle solutions for chronic infected wounds and other uses to promote infection control and regenerative tissue therapy. BioLargo also owns a 50% interest in the Isan System, a fully automated iodine dosing system being commercialized under a license to Clarion Water, Inc (www.ClarionWater.com).  

Safe Harbor Statement
The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, the risks and uncertainties included in BioLargo’s current and future filings with the Securities and Exchange Commission, including those set forth in BioLargo’s Annual Report on Form 10-K.

Company Contact
Dennis Calvert
President and CEO
BioLargo, Inc.
949-643-9540 x2

Thursday, 1 February 2018

Company Progress Report - Dennis Calvert Interviewed by Uptick Newswire

BioLargo CEO Dennis Calvert returned to Uptick Newswire Stock Day Podcast with Everett Jolly today to deliver an important and welcome update on the company's progress in its multiple advancing businesses.

BioLargo has seen numerous successes in recent weeks, both in new contracts and sales, and in crucial developments for its disruptive water treatment platform, the Advanced Oxidation System (AOS):

Odor-No-More/CupriDyne Clean Industrial Odor Control:
  • Sales are accelerating
  • Winning new customers constantly, and spreading across the country rapidly
  • Once a customer tries CupriDyne Clean, they never go back to our competitors. Our product provides vastly superior performance, at a significant cost savings
  • Expanding uses! Customers using CupriDyne Clean to control VOCs
BioLargo Engineering (BLEST):
  • Roughly 10 new customer accounts!
  • Opportunities and invitations rapidly accelerating - team's professional credibility paying dividends
  • Internal work is accelerating AOS development
Clyra Medical:
  • Quietness of Clyra Medical is due to impending FDA 510(k) decision on our products
  • Average FDA 510(k) application takes 177 days. We are only just past 100 days, and we are confident about the application
  • Huge opportunity, simply waiting for regulatory approval
  • Patience is required
Advanced Oxidation System (AOS):
  • Our science is proven
  • Development is progressing for pilot prototype of AOS - being advanced by our new engineering unit
  • Recently attended Canadian government-sponsored trade mission in China where there was big interest in AOS for pilots and trials in China
  • China is flush with cash, has significant water issues and is hunting for solutions like the AOS.
  • Engineering team is developing a full scale-up strategy and plan to create a full-scale AOS, which will be implemented soon
  • AOS now been demonstrated potentially disruptive to important and huge water treatment segments like:
    • Storm water treatment
    • Removal of selenium
    • Pharmaceuticals
    • Protozoan parasites (eg. Cryptosporidium)
    • Viruses
  • Proven the AOS capable of treating highly contaminated real-world water sources like:
    • Secondary and tertiary municipal wastewater
    • Poultry processing wastewater
    • Contaminated river water 

Wednesday, 10 January 2018

Tamarack Article - Industrial Odor Control is Big Business

DENVER, CO / ACCESSWIRE / January 9, 2018 / BioLargo®, Inc. (OTCQB: BLGO):

More than one million industrial sites in the U.S. generate unpleasant odors as a normal part of their operations. Although the U.S. waste handling industry makes up only a small part of that million, its revenues exceed $75 Billion annually. Landfills, transfer stations, composting operations, and countless trash containers harbor some of the most putrescent odors imaginable. With increasing urbanization, our neighborhoods creep closer and closer to these facilities, triggering more frequent complaints, regulatory violations, and in extreme situations, litigation.

To combat regulatory violations, neighbor complaints, and lawsuits, the waste handling industry has historically relied on odor control products that use strong fragrances to try to overpower unpleasant odors. Some companies have even installed expensive covers and enclosures to mitigate the negative impact of odors on their neighbors. While solutions like these have historically been considered the “best available,” these old strategies do not go to the root of the problem – the odor-causing compounds themselves – and therefore tend to fail. While some enzyme-based solutions do eliminate some odor-causing compounds, they often have a limited range of activity, take some time to work, and can be costly. The industry has been ripe for innovation to find a product that actually works to eliminate the odor causing compounds like hydrogen sulfides and ammonia.

BioLargo®, Inc. (OTCQB: BLGO) first launched CupriDyne Clean in May of 2016. In the first year of its commercialization the company proved the commercial viability of CupriDyne Clean. By July of 2017, it had landed as clients 3 of the top 10 companies in the solid waste handling industry. The company’s filings show CupriDyne Clean sales have doubled each of the first three quarters of 2017.

With sales to waste handling facilities gaining traction, BioLargo reports it is looking to sell CupriDyne Clean into new industries. Its last quarterly report stated that it was conducting trials in the wastewater treatment industry, and its recent shareholder letter indicated it had secured its first flagship clients. Wastewater treatment is a big industry – there are more than 900 public wastewater treatment facilities in California alone. 2015 Census figures report 740,303 active firms (including municipalities and private companies) in California, representing just under $1 billion in payroll. There are more than 6,000 California firms employing more than 500 people in the industry. According to Global Information, a market research company, the global municipal and industrial wastewater sludge treatment equipment and wastewater/sludge-based odor control equipment is estimated to have been $6.5 billion in 2013, and reached an estimated $6.9 billion by year-end 2014. The compound annual growth rate (CAGR) during the forecast period, 2014 to 2019, is estimated to be 5.9%. At this rate, the market value could reach $9.2 billion by 2019.

In a special Waste360 report, Joseph Provenzano, President of BioLargo’s Odor-No-More® division explained, “CupriDyne Clean oxidizes all volatile organic compounds (VOCs), amines, sulfur compounds, fatty acids, and mercaptans prevalent at sites that process organics. Our products are broad spectrum and work indiscriminately on all organically derived odors. They eliminate odors rather than cover them. Most other industry products use fragrance to mask odors, often exacerbating the problem. Our products are not masking agents. Rather, this green technology breaks down odorous compounds through oxidation. Odor reduction is immediate and it is safe.”

BioLargo is a sustainable engineering services, science and technology company with multiple irons in the fire, with its focus on clean air, clean water and advanced wound care. According to its year-end Shareholder Letter, its industrial odor eliminator product CupriDyne is poised for exponential revenue growth. Its new sustainable environmental engineering services team is commercial and has landed its first customer contracts for 2018. Its advanced wound care products are in FDA review with expectations to go commercial in early 2018. Its award-winning advanced water treatment technology is targeting late 2018 to go commercial. BioLargo is a company to watch as it continues to build its business and focus on its mission to “Make Life Better”.

Legal Disclaimer:

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Flathead Business Solutions LLC, which owns tamarackadvisorsinc.com, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. Flathead Business Solutions LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Flathead Business Solutions LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit http://tamarackadvisorsinc.com/legal-disclaimer/.

SOURCE: Tamarack Advisors

Thursday, 28 December 2017

Shareholder Letter: BioLargo Wishing You a GREAT 2018 - Short Review of the Past - Present - Future

BioLargo Wishing You a GREAT 2018

Dear Shareholder,

This is always a good time of year for us to review the past, take inventory of the present, and lay out our goals and aspirations for the future. 

Past: 2017 Was a Good Year for BioLargo

Notable Milestones:
·      Clyra secured dedicated financing, concluded product development, and filed its first FDA 510(k) application (still in process) for its advanced wound care products.
·      Odor-No-More proved the market opportunity for our CupriDyne Clean products by doubling sales each of the first three quarters of the year. We also secured national purchasing agreements with three of the top ten US solid waste handling companies (more coming soon), and secured our first flagship clients in the wastewater treatment industry.
·      We acquired a world-class environmental engineering team – BLEST – that previously served two global, industry-leading firms, with more than 200+ years of field experience. This team helped respond to several well-known natural and industrial disasters including; Katrina & Haiti rebuild, US anthrax attacks, and extremely difficult industrial challenges like dioxin remediation. They are also notable technology developers, which is why we chose them to form BioLargo Engineering, Science and Technologies (BLEST). They have already entered into their first six contracts to serve clients in 2018, and are actively pursuing a wide range of business opportunities while also serving BioLargo in the scale-up and engineering of the company’s advanced water treatment technology.
·      BioLargo Water’s advanced water treatment technology, the AOS (Advanced Oxidation System), has received over 50 government and industry research grants (and counting) since the company was formed approximately three years ago. The company recently completed three commercial proof-of-claim trials and added highly qualified professionals to the team. A number of commercial projects are being considered for the AOS.
·      Our company won numerous awards and recognitions this year, including a highly coveted 2017 High Tech Innovation Award Winner in the Horizontal Disruption category by the Orange County innovation cluster OCTANe, and The Most Promising Technology Growth Award for 2017 by Uptick.
·      BioLargo secured important capital resources when it entered into a common stock purchase agreement with Lincoln Park Capital for up to $10 million of equity capital, priced at the market, and subject to certain terms and conditions as described in the Form 8-K we filed on August 31, 2017.
·      Total direct investments in BioLargo surpassed $20 million since the company’s inception in 2007.

Was this a good year?  Yes.

Are we satisfied? No. 

We are never satisfied until we deliver GREAT results in all categories and with all our business units.

We can all agree that we all want more commercial adoption and more financial success. And we want it faster. Let’s face it – conceiving, creating, developing, and successfully launching disruptive technologies (three and counting) for multi-billion dollar markets is not easy, it is not fast, and it cannot be done without proper capital resources.  

Are we winning? Definitely.

Our mission to build BioLargo and make life better has required significant investment of time, energy, and money.  It has demanded that we assemble an incredibly talented team of highly qualified scientists, engineers, and business development professionals. We weathered one of the worst economic disasters in history soon after the inception of our company in 2007.  We have endured numerous business setbacks as we pursued licensing relationships in our early years. We have been honored to receive investments from more than 400 investors. Our journey represents a life’s work for our founder Kenneth Reay Code. For me, Dennis Calvert, I consider my work at BioLargo to be one of the most important and worthy pursuits of my career. Ken and I, as well as our core management team, have remained steadfast and undeterred, investing directly in the early years, and all the while electing to convert salaries to BioLargo shares when the company needed to conserve cash. And, we’ve never sold those shares. We continue to stretch our company, our team, and ourselves, and we choose to defer our financial rewards for one simple reason: because we know it will be worth it.

Present: Cornerstones of Success

We have two active commercial operations and two future operations scheduled to go commercial in 2018. Our industrial odor control division, Odor-No-More, which launched its industrial odor control product CupriDyne Clean in May of 2016, is poised for enormous growth this year. The same can be said of our brand-new engineering group, BLEST. 

Clyra will be ready to go commercial when its products receive FDA approvals.  It submitted its first FDA 510(k) application at the end of September, and is working to provide the FDA additional information as required to keep it moving towards completion. Emergo, our FDA consultant and a leader in the industry, reminds us to be patient, as it reports that in 2016 the average time frame for these types of applications was 177 days.  So, we have a bit of work to do, but remain highly optimistic about our expected success in this process.

As for our AOS water treatment technology, we are smack in the middle of the famous technology adoption gap that author Geoffrey Moore coined as the “Chasm” .  We believe our AOS will cross over to commercialization very soon, and we will achieve this by advancing our claims and by supporting the next phase of engineering and scale-up (now that we have the talent on-board with BLEST). We are refining our technical offerings and claims and working to find adoption by pursuing large public funding opportunities, potential strategic alliances and/or investment, and by focusing on first-stage commercial opportunities where we can deliver value to our customers, such as in industrial wastewater treatment.

Future: Building a GREAT Company in BioLargo

Do we predict significant financial success for BioLargo’s future? Absolutely.

BioLargo’s evolution has been careful, deliberate, and by any account, amazing. Our company is first and foremost a sustainable science and technology innovator. We now have added the go-to-market talent through our environmental engineering services group, BLEST, complemented by an extensive team of highly qualified scientists and business development professionals, to help serve clients solve serious, real-life problems. We are highly purposeful in our selection of target applications and markets, choosing to focus where we can make an impact for good, and where we believe our technology will serve as a disruptive force for change, as illustrated by our slogan, “we make life better”.

What are our target milestones for 2018?

We have a series of specific targets upon which we will focus to enable the successful commercial future that we believe to be imminent.

·      Secure FDA approval for Clyra, and acquire additional technology assets to round out Clyra’s Offering to go-to-market in 2018. We hope to secure dedicated capital and position to spin off the company when the timing is right to benefit BioLargo’s and Clyra’s shareholders.Secure large public and/or strategic funding to support the AOS’s scale-up, engineering, and commercial launch.
·      Accelerate and increase sales, marketing and service teams for Odor-No-More to create positive cash flow.
·      Achieve cash flow positive status for BLEST.
·      Uplist to NASDAQ to create national market for our stock.
·      Continue adding highly qualified staff, including additional talented administrative team members for the corporate office.
·      Continue the company’s evolution to become an integrated solution provider with services, industry knowledge, rare science skills, and sought-after technologies and products to solve real life problems.

In closing: we love our company and are committed to achieving significance, both in terms of our commitment to a greater good as evidenced by our mission to make life better, while at the same time deliver a handsome return on investment for our stockholders. 

We are thankful for you and your support.  


 “Nothing Great is Easy”

- Matthew Webb
The first man to swim the English Channel

BioLargo is a GREAT company and we believe 2018 will be a GREAT year.

Happy New Year!


Dennis P. Calvert
President & CEO
BioLargo, Inc.

Tuesday, 28 November 2017

Tamarack Advisors Article: BioLargo Achieves Important Commercial Milestones for Clean Water, Clean Air and Advanced Wound Care Markets

Below is an article by Tamarack Advisors published this morning that contains a deep and in-depth interview with BioLargo President and CEO Dennis Calvert. Access the article directly here, or read on below!


DENVER, CO / ACCESSWIRE / November 28, 2017 / While covering BioLargo (OTCQB: BLGO), Tamarack Advisors has watched the company advance its disruptive technologies in the large markets of water treatment, air quality/treatment, and advanced wound care. It’s been a long journey that has tested management and investors, but for those patient investors that held on, the company’s most recent press release and 10Q filing could signal a tipping point. The company is beginning to deliver sales on one of its many award-winning products, and appear poised for considerable growth in the years to come.

BioLargo recently reported on their progress in a press release. Tamarack Advisors sat down with BioLargo’s CEO, Dennis Calvert to learn more about BioLargo’s progress.

Tamarack Advisors: 

You’ve claimed that CupriDyne Clean is the only odor control product used by the waste handling industry that actually works, breaking down odor-causing compounds without using masking fragrances. The solid waste industry and wastewater segments are sizable verticals for BioLargo to target. Having said that, what will it take for the company to generate sales in the $300,000 per month or $4,000,000 annual range or greater?

Dennis Calvert:

The short answer is that we are just getting started with CupriDyne Clean. The three National Purchasing Agreements already in place and our new engineering division, BioLargo Engineering Science & Technologies set the stage for our continued expansion, as our existing customers expand the use of our products across their very large organizations. We are pleased to see these early-stage revenues because they are a good indicator of industry adoption and we do expect our sales to grow far more quickly as we break out within these companies. We also have additional corporate accounts in the works. We believe our sales will grow faster and should even exceed those figures. How will we do this? We’ll continue to sell our way up to the top decision makers who control the deployment of solutions like ours for large national companies. We will invest in more sales and support staff to support the growth. We will increase our marketing efforts to help get the word out. We are also starting to expand CupriDyne Clean into new markets, such as wastewater treatment facilities. There are more than 900 public wastewater treatment facilities in California alone, and our first clients are some of the largest and most well-known operations in the industry. To help understand the size of the wastewater treatment industry, the 2015 Census figures report that the total wastewater industry in California alone includes 740,303 active firms (including municipalities and private companies) and represents just under $1 billion in payroll. The number of large California firms employing more than 500 people is reported at 6,060 representing about 50% of the total payroll for the California industry alone.

Tamarack Advisors:

How has the acquisition of your new engineering division changed things for CupriDyne Clean? How do you expect that to accelerate market adoption of this product?

Dennis Calvert:

Our recent addition of the company’s new in-house engineering team is allowing us to expand our capabilities and open new opportunities with existing and new clients. For example, one client has asked us to design and build a portable misting system that could deliver our CupriDyne Clean product over the surface of a landfill. Our engineers are working on the project as we speak. In another example, our engineers recently conducted a small study that shows our CupriDyne Clean can eliminate some dangerous contaminants out of a gas plume, which refers to the flow of pollutants in the form of vapors or smoke released into the air like you might see coming from a power generation plant. Early success in this study points to expanding high-value uses of the product to help maintain air quality for industry. Our continued success working with clients to manage VOC’s (Volatile Organic Compound) is an expanding market well beyond simple odor control.

We believe CupriDyne Clean may provide solutions to a number of very large industrial operations we haven’t even considered yet, helping maintain and improve air quality for numerous industries. And, now we have the team on board with the experience and knowledge to serve these customers. We are exploring multiple commercial opportunities.

Tamarack Advisors:

Assuming you can capture a good segment of the odor control and air quality control market – does that mean the opportunity for CupriDyne Clean is a $15 to $20 million annual business or is it potentially bigger?

Dennis Calvert: 

We believe the potential is much bigger! The international markets are also quite large, and we are just now able to invest some time and money pursuing those markets. Most recently, we participated in a trade mission to China which helped us understand the needs in this area. Their air quality problems are widely reported. The trade mission allowed us to sit and talk with more than a dozen industrial companies that all expressed interest in the large and important odor and air quality control markets there, and rolling out CupriDyne to China, something we are working on currently.

Tamarack Advisors:

BioLargo is arguably best known for its breakthrough in water treatment with the AOS, (Advanced Oxidation System). We understand and agree that projecting sales is difficult, but can you tell us where BioLargo is in terms of its expectation of first revenues from this $860 billion market?

Dennis Calvert:

The AOS is one of our star products for sure and you are correct, newly developing sales are very difficult to forecast. We are quite proud of the fact that even though our first foray into the water industry began only 3 years ago, our breakthrough technology is already nearing its commercial launch. The first research project, I’ll remind you, was a research project at the University of Alberta to help solve the contaminated water issues around the oils sands industry. Until then, the AOS technology was just an idea. Our success in that early proof of claim work encouraged us to start BioLargo Water. Now, after three years of hard work, we have arrived at this point with a proven technology, a number of strategic relationships, over 50 government grants, and the early attention of a very large $860 billion industry as an up-and-coming contender. Of course, there is work to do to get our AOS seated in the marketplace and we are facing the important task of scaling up the technology with our new engineering team. We believe our proven AOS value propositions of high performance and low cost will be the successful drivers to make it happen.

Tamarack Advisors:

What’s your strategy for monetizing the AOS?

Dennis Calvert:

We are very active in pursuing three pathways to monetize the AOS: first, acquire large grants from public funding agencies to help us break through to commercialization via rigorous commercial piloting. Second, develop strategic alliances with larger companies; and third, pick a segment and go direct-to-market. We are working diligently and are highly encouraged by a long list of stakeholders in each area to continue to pursue all three strategies and I can confidently predict our inevitable success with this product because of this.

With respect to funding grants, we have been awarded more than 50 research grants and climbing, from various Canadian public and private agencies, including the Canadian National Research Council – Industrial Research Assistance Program (NRC-IRAP) and the National Science and Engineering Research Council of Canada (NSERC). Through a project funded by a grant from the Metropolitan Water District of Southern California pursuant to its Innovative Conservation Program, we confirmed the technical capabilities of our AOS system to disinfect and decontaminate poultry, dairy and municipal tertiary effluent wastewater. We are engaged in active discussions with a number of very large funding agencies and are preparing formal submissions to occur in the near term.

With respect to strategic alliances, we have a number of ongoing discussions under NDA with leading companies in industry. These include dedicated water treatment companies and actual corporate clients from specific industries like food processing, where we have already completed significant testing to prove our claims. Our scale-up work with our engineers is critical to support these discussions and we believe that we will find success in this area as that work is completed. We expect to more fully report on our work in this area in the coming months. As for timing, we could see early revenues from our AOS in 2018, depending on the status of our strategic licensing and grant efforts. This opportunity has an enormous potential to become very big, very fast. Our go-direct-to-market efforts could have us in the field in late 2018.

Tamarack Advisors:

Let’s change gears and talk about your subsidiary, Clyra Medical. Wound care is an $18 billion-dollar industry that appears to have a substantial unmet need for better solutions because of stubborn and difficult-to-treat wounds such as diabetic wounds, pressure wounds, antimicrobial resistance, and the high cost of current solutions. You recently submitted a 510(k) application for your Clyra Medical product – what can you tell us about this?

Dennis Calvert:

Our wound care products are very exciting because we figured out how to incorporate the ”gold standard” of antimicrobials – iodine – into products without its traditional cytotoxicity issues. In addition, our third-party testing also confirms that the product has some extended antimicrobial efficacy which makes it a perfect complement to an infection control and regenerative tissue therapy strategy. So, I suppose in summary, the applications for our products are broad and extremely important.

In late September, Clyra submitted an application for premarket notification under Section 510(k) for a wound care product. It is now in the formal 90-day review process by the FDA, which we hope is completed around the end of the year or in the first part of 2018. In anticipation of FDA approval of this first product, and of additional products already in development, Clyra accepted $1,000,000 of investments, $250,000 of which was from BioLargo.

Tamarack Advisors:

So, once the FDA process is complete, how is Clyra going to commercialize your technology in the medical field? What are its future plans?

Dennis Calvert:

For the wound care product under FDA submission, Clyra’s management is actively engaged in arranging for clinical work with what are called ”key opinion leaders.” For example, you may have seen our reporting about Dr. Brock Liden’s involvement. Dr. Liden is a practicing wound care specialist physician and has been working with our technology for some time. Additionally, Clyra management has had discussions with multiple potential strategic partners for distribution or licensing of the initial wound care product. These discussions are dependent on a successful FDA process and have been preliminary in nature, so we will have to wait and see on their success.

As far as future plans, Clyra has two additional products that are far along in the development stage. Once ready, they will be submitted to the FDA under the same 510(k) process. We’re very excited about those additional products – one is in the dental field – and we will announce them as soon as Clyra’s ready to do so.

Tamarack Advisors:

Having followed your company for quite some time, we were quite surprised when you announced the acquisition of an in-house engineering team. What advantages do you see it providing? How will it help BioLargo make money?

Dennis Calvert:

We had been working with this group of lead engineers since 2016 through our relationship with Chicago Bridge & Iron (NYSE: CBI). When a large division of CB&I was sold, managing Engineer Randy Moore and his team became available and reached out to us. The decision to bring them in-house was easy. As lead engineers with one of the largest engineering companies in the world, the team has incredible backgrounds working to solve some of the most well-known natural and industrial challenges in recent history. As lead technical innovators serving clients around the world, our team is equipped to address even the most demanding situations in the marketplace.

We expect our engineers to help the company in three primary ways – through the provision of professional services to outside clients; commercializing AOS; and by developing technologies for our other existing products.

With respect to outside professional services, our team is currently evaluating, bidding, negotiating, and generally pursuing commercial opportunities. They have decades of relationships with clients that require their services and are reaching out to those clients. They are also providing subcontracted services to CB&I (their former employer) which has recently been sold and is now known as APTIM.

With respect to AOS, the team is taking the AOS from the lab to the field. In the coming months, they will be working to design a pilot-ready system capable of field-testing and subsequent commercialization.

They are also there to assist with existing products. Just last week, they met with one of our industrial odor clients to design and build a portable system that can deliver our CupriDyne Clean product to the surface of landfills for odor control.

Engineering in itself can be a very large business and now we have a world-class team to serve our internal and external client needs.

Tamarack Advisors:

Thanks for your time Dennis. Any final comments?

Dennis Calvert:

We are enjoying the flywheel effect and its momentum is powerful. We are often reminded that our continued focus on our worthy mission to Make Life Better through innovation, as well as our continued ability to attract exceptionally qualified talent and the support of our investors and public funding sources, are all critical components to our success. Technologies like ours can be a catalyst for change for good and we are a living testimony to the power of innovation combined with purpose for the greater good. In many ways, we are just getting started and we can’t wait for tomorrow. I encourage our stakeholders to read the updates in our recently filed quarterly report with the SEC for a complete understanding of the highlights in this interview.

Tamarack Advisors:

Thanks, Dennis, we are very excited to report on your progress in the coming weeks and months.

Legal Disclaimer:

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Flathead Business Solutions LLC, which owns tamarackadvisorsinc.com, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. Flathead Business Solutions LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Flathead Business Solutions LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit http://tamarackadvisorsinc.com/legal-disclaimer/.

SOURCE: Tamarack Advisors